Article

Fellow eye study finds efficacy and benefits for photochromic IOL

Results from a study evaluating the first photochromic IOL (Aurium, Medennium) indicate that it provides stable and effective pseudophakic correction and outperforms a yellow IOL under mesopic conditions, said David Mendez Noble, MD, Mexicali, Mexico.

Results from a study evaluating the first photochromic IOL (Aurium, Medennium) indicate that it provides stable and effective pseudophakic correction and outperforms a yellow IOL under mesopic conditions, said David Mendez Noble, MD, Mexicali, Mexico.

The photochromic IOL responds to environmental changes so that it provides blue-blocking protection only as needed. Under conditions in which there is low ultraviolet (UV) light, the optic is clear and does not block blue light, but it changes quickly to yellow in the presence of UV light so that it is able to block the higher levels of blue light that are present in sunlight.

The performance of the photochromic IOL was investigated in a study enrolling 15 patients with the photochromic IOL implanted in one eye and a yellow aspherical IOL (AcrySof IQ [SN60WF], Alcon Laboratories) implanted in the fellow eye. Best-corrected visual acuity (BCVA) was measured indoors at various follow-up visits using Snellen charts with lighting conditions being increased over the range from 11 to 1,200 lux. BCVA also was checked at 30 days postoperatively outdoors, with and without sunglasses worn.

The BCVA results indicated the photochromic IOL was effective and provided vision that was stable through 2 years. In the indoor testing, BCVA increased with both IOLs as the illumination levels increased, but the photochromic IOL outperformed the aspherical IOL in low-level illumination conditions. In the outdoor testing, little difference was found between BCVA measured with and without sunglasses in the photochromic IOL eyes, whereas putting on sunglasses negatively impacted BCVA in 11 eyes with the aspherical IOL.

"Permanently yellow IOLs block 50% of blue light, but there is debate over whether such lenses have a negative impact on night vision, color vision, and the circadian cycle," Dr. Noble said. "The [photochromic IOL] is designed to provide all the benefits of a blue light-blocking IOL without any of the potential downsides."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.